All In Biotech

Company

Alkermes INC

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

5

5 still marketed

Novel approvals

2

Approvals since 2021

4

Originals and new uses

Phase 3 trials

34

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (3)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • ALKS 2680AlixorextonPhase 37 trials

    Alkermes, Inc. · Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

  • OLZSAM, ALKS 3831Phase 32 trials

    Alkermes, Inc. · Bipolar I Disorder, Schizophrenia

  • ALKS 7290Phase 21 trial

    Alkermes, Inc. · Attention Deficit Disorder With Hyperactivity (ADHD)

Recruiting Phase 3 trials

Largest first.

Marketed drugs (5)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.